Date: 2012-06-19
Type of information: R&D agreement
Compound: G-protein coupled receptors (GPCRs), and other transmembrane proteins
Company: Heptares Therapeutics (UK) Medical Research Council - MRC (UK)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: The US GPCR drug discovery company, Heptares Therapeutics has extended its collaboration with the UK Medical Research Council (MRC), including its leading research groups at the MRC Laboratory of Molecular Biology (LMB, Cambridge, UK) and MRC National Institute of Medical Research (NIMR, London, UK), on the structure and active conformations of G-protein coupled receptors (GPCRs), and other transmembrane proteins. Building upon their existing relationship with the MRC, and in particular the group led by Chris Tate at the MRC LMB – an internationally recognised expert in structural biology of integral membrane proteins – Heptares will own certain IP and technology in the field, including that pertaining to agonist-induced GPCR states responsible for cell signalling, a key area for drug design.
Financial terms:
Latest news:
